The invention encompasses novel N-alkyl-hydroxamic acid-isoindolyl compounds,
pharmaceutical compositions of these compounds, and methods of using these compounds
and compositions for treatment or prevention of various diseases and disorders,
for example, diseases associated with PDE4.
